Replay: Corp. Access: ZEAL C-Suite CEO call: Petre Amylin positioned as 1L obesity backbone; Survo tolerability debate continues despite potential liver edge

Research evidence excerpt

Replay: Corp. Access: ZEAL C-Suite CEO call: Petre Amylin positioned as 1L obesity backbone; Survo tolerability debate continues despite potential liver edge

Equity Research

24 June 2026

Replay: Corp. Access

ZEAL C-Suite CEO call: Petre

Amylin positioned as 1L obesity

backbone; Survo tolerability European Pharmaceuticals,

Biotechnology & Life Sciences

Yihan Li, PhDdebate continues despite potential

+44 (0)20 3555 3563

yihan.li@barclays.comliver edge Barclays, UK

James GordonCEO Adam Steensberg framed petrelintide as a tolerability

and persistence-led 1L amylin therapy, with +GLP-1/ +44james.gordon@barclays.com(0)20 7116 2784

GIP combo optionality for higher-need patients, while Barclays, UK

defending survodutide's (GLP-1/GCG) liver/lean mass Sidhartha Modi

+91 (0)22 6175 1326

differentiation despite GI tox concerns. sidhartha.modi@barclays.com

Barclays, UK

Charles Pitman-King, CFA

Please see below replay information for the event held on +44 (0)20 3134 6023

charles.pitman-king@barclays.com Monday, 22 June 2026 at 2:00pm – 3:00pm UTC

This replay is strictly and solely for the benefit of the intended recipients. Barclays Events Terms of

Service and the Barclays Events Privacy Notice

Watch

Appearances by Third-Party Speakers: Any views or opinions expressed by third-party speakers

during this event are solely those of the speaker and do not represent the views or opinions of

Barclays. Barclays is not responsible for, and makes no warranties whatsoever as to, the

information or opinions contained in any written, electronic, audio or video presentations by any

third-party speakers at the event (“Third-Party Content”). Any such Third-Party Content has not

been adopted or endorsed by Barclays and does not represent the views or opinions of Barclays.